RESMED INC
For the period ended Mar 31, 2024. Filed Apr 26, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed Apr 26, 2024
RMD$234.11-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations (Unaudited)
| PART I – FINANCIAL INFORMATION | Item 1 |
|---|
Condensed Consolidated Statements of Operations (Unaudited)
(In US$ and in thousands, except per share data)
| Three Months EndedMarch 31, | Nine Months EndedMarch 31, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Net revenue - Sleep and Respiratory Care products | $1,049,023 | $980,116 | $3,029,915 | $2,741,541 |
| Net revenue - Software as a Service | 147,957 | 136,782 | 432,187 | 359,395 |
| Net revenue | 1,196,980 | 1,116,898 | 3,462,102 | 3,100,936 |
| Cost of sales - Sleep and Respiratory Care products | 448,434 | 443,925 | 1,353,615 | 1,214,072 |
| Cost of sales - Software as a Service | 47,953 | 46,899 | 143,735 | 126,588 |
| Cost of sales (exclusive of amortization shown separately below) | 496,387 | 490,824 | 1,497,350 | 1,340,660 |
| Amortization of acquired intangible assets - Sleep and Respiratory Care products | 1,054 | 1,367 | 4,294 | 3,939 |
| Amortization of acquired intangible assets - Software as a Service | 6,758 | 6,955 | 20,682 | 18,062 |
| Amortization of acquired intangible assets | 7,812 | 8,322 | 24,976 | 22,001 |
| Total cost of sales | 504,199 | 499,146 | 1,522,326 | 1,362,661 |
| Gross profit | 692,781 | 617,752 | 1,939,776 | 1,738,275 |
| Selling, general, and administrative | 229,919 | 228,457 | 674,948 | 633,317 |
| Research and development | 77,074 | 76,436 | 226,664 | 209,498 |
| Amortization of acquired intangible assets | 11,204 | 12,188 | 35,259 | 29,701 |
| Restructuring expenses (note 11) | — | — | 64,228 | — |
| Acquisition related expenses | — | — | — | 9,157 |
| Total operating expenses | 318,197 | 317,081 | 1,001,099 | 881,673 |
| Income from operations | 374,584 | 300,671 | 938,677 | 856,602 |
| Other income (loss), net: | ||||
| Interest (expense) income, net | (11,026) | (14,964) | (39,787) | (32,436) |
| Gain (loss) attributable to equity method investments (note 5) | 440 | (183) | (2,716) | (5,037) |
| Gain on equity investments (note 5) | 13,919 | 6,418 | 11,429 | 11,506 |
| Other, net | (2,496) | (2,564) | (537) | (5,773) |
| Total other income (loss), net | 837 | (11,293) | (31,611) | (31,740) |
| Income before income taxes | 375,421 | 289,378 | 907,066 | 824,862 |
| Income taxes | 74,929 | 56,878 | 178,351 | 156,970 |
| Net income | $300,492 | $232,500 | $728,715 | $667,892 |
| Basic earnings per share (note 8) | $2.04 | $1.58 | $4.96 | $4.55 |
| Diluted earnings per share (note 8) | $2.04 | $1.58 | $4.94 | $4.53 |
| Dividend declared per share | $0.48 | $0.44 | $1.44 | $1.32 |
| Basic shares outstanding (000's) | 146,959 | 146,914 | 147,056 | 146,681 |
| Diluted shares outstanding (000's) | 147,450 | 147,395 | 147,549 | 147,400 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.